BioWorld looks at translational medicine, including: Picturing molecular alterations; Fishing for druggable osteoporosis targets; First mouse-adapted strain of SARS-CoV-2; Transplanted iPSCs are best of both ApoE models; TXNIP inhibition nixes T2D; Degradation approach targets extracellular proteins; Tryptophan metabolites keep gut barrier strong; Honest placebos change brain potentials; Screening in serum yields active antibiotics.
Six months to the day that the World Health Organization (WHO) declared it a public health emergency, the SARS-CoV-2 virus, with its hideous red spikes, continues to taunt the world, hopping from host to host and haunting humans, many of whom wonder the same thing: What’s next?
There were no surprises among the latest rankings in JLL’s Life Sciences Outlook report, which tracks geographic shifts in life sciences innovation, operations and facilities investments, and includes an analysis of markets actively investing in their life sciences sectors. Boston, San Francisco and San Diego once again occupied the top three spots as the leading U.S. life science clusters.
Biopharma companies that are focused on cell therapies have reported promising clinical trial results in their ability to treat acute respiratory distress syndrome (ARDS), a condition that has shown to be a significant contributor to higher mortality in COVID-19 cases.
RSS
